TRC102 (methoxyamine) is a novel, clinical-stage small molecule inhibitor of the DNA base excision repair pathway, which is a pathway that causes resistance to alkylating and antimetabolite chemotherapeutics. TRC102 is currently being studied in multiple Phase 1 and Phase 2 clinical trials sponsored by the National Cancer Institute or Case Comprehensive Cancer Center.

TRC102 Scientific Presentations

Eads et al Investigational New Drugs 2020 (TRC102 + Temodar Phase 1 trial)
ASCO 2020 Phase 2 TRC102 + Alimta/Phase 1 TRC102 + Alimta + cisplatin Poster
ASCO 2020 TRC102 +chemoradiation in lung cancer Phase 1 Poster
2019 AACR TRC102 + Temodar Phase 2 Poster
2017 ASCO TRC102 + Temodar Phase 1 Poster
2016 ASCO TRC102 + Temodar Phase 1 Poster
2015 ASCO TRC102 + Temozolomide Phase 1 Poster
2015 AACR TRC102 + Temozolomide Phase 1 Poster
2014 ASH TRC102 + Fludarabine Phase 1 Poster
2012 AACR TRC102 + Temodar Phase 1b poster
2012 AACR TRC102 + Temodar Phase 1b PK data poster
2010 ASCO – Phase 1 slideshow
2010 ASCO – Phase 1 poster
2010 AACR– preclinical poster
2009 AACR– 3 preclinical posters
2007 EORTC-NCI-AACR

TRC102 Journal Publications

Caimi PF, et al. TRC102 + Fludara Phase 1 Trial
Gordon MS et al Investigational New Drugs 2012 (TRC102 Phase 1b)